CKD stage III and IV patients with aged over 65 yrs Sarcopenia,
Conditions
Interventions
60 % Leucine in BCAA = 4.5 g/day,Placebo
Experimental Dietary Supplement,Placebo Comparator No treatment
Leucine,Placebo
Sponsors
None
Eligibility
Sex/Gender
All
Age
65 Years to No maximum
Inclusion criteria
Inclusion criteria: Age >65 years old eGFR 30-59 ml/min/1.73m2 Signed informed consent No contraindication for leucine
Exclusion criteria
Exclusion criteria: Catabolic stage Active infection Active malignancy Diabetes Liver disease Vascular disease Cardiac abnormalities Metabolic disease or injury No history of steroid used
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To demonstrate the effect of 12-weeks leucine supplementation on muscle mass and protein synthesis i at 12 weeks after start of the intervention Lean muscle mass form DXA Scan | — |
Secondary
| Measure | Time frame |
|---|---|
| Risk factors of sarcopenia in elderly chronic kidney disease patients at 12 weeks after start of the intervention Laboratory profile | — |
Countries
Thailand
Contacts
Public ContactNeti Sunsandee
Division of Nephrology, Department of Medicine, Phramongkutklao Hospital and College of Medicine
Outcome results
None listed